Positive Topline Data for Lilly ' s Donanemab in Early Alzheimer ' s Positive Topline Data for Lilly ' s Donanemab in Early Alzheimer ' s

Donanemab, which targets a modified form of amyloid, slowed decline of a composite measure of cognition and function by 32% relative to placebo, topline phase 2 results show.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Neurology & Neurosurgery News Source Type: news